A Phase 4 interventional study of Pancreatin and Placebo in Type 2 Diabetes (T2DM), sponsored by Silesian Centre for Heart Diseases. Recruiting at 1 site in Poland. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Silesian Centre for Heart Diseases · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 27 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 303rd largest by planned enrollment of the 333 interventional ones that give a count, is one of 23 that started in 2026, is one of 28 in phase 4, reaches primary completion later than 14 of the 37 other live ones, and was the 345th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →27 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Bialystok · Sites in Poland
Ages 18–65
Ascletis Pharma (China) Co., Limited · Sites in Poland, United States, Czechia and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in Poland, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Poland, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Poland, United States, Australia and 10 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 67 · Phase 3 220 · Phase 4 28
First in 2001; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 500 across the 333 interventional studies, 3,039 across the 18 observational. Of the 307 that completed or were terminated, 203 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
335 of 351 have an industry lead sponsor. The 10 most frequent:
Silesian Centre for Heart Diseases is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
Silesian Centre for Heart Diseases has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 2 with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from the small intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. They play a role in regulation of blood glucose levels, particularly postprandial glycemia. Lipids and carbohydrates are the most potent stimulators of incretin hormone secretion. Pancreatin is a mixture of digestive enzymes naturally produced by the pancreas, which is used as a medication supporting macronutrient digestion, especially in cases of exocrine pancreatic insufficiency. Evidence suggests that oral pancreatin supplementation enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. Based on a randomized, placebo-controlled, double-blind study, we aim to evaluate the effect of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.
We plan to recruit a total of 100 patients with type 2 diabetes treated with oral antihyperglycemic drugs or insulin, either as monotherapy or in combination. Patients will be randomly divided into 2 groups:
Baseline assessment:
Assessment after study completion:
Should pancreatin demonstrate a beneficial effect on glycemic homeostasis, these formulations could serve as a valuable adjunctive therapy for type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving pancreatin
Drug: Pancreatin
Participants receiving placebo
Drug: Placebo
Pancreatin 25 000 U with each of the 3 main meals daily for 3 months
Also known as: ActiveLab
Placebo capsule with each of the 3 main meals daily for 3 months
Also known as: ActivLab Placebo
Glycemic control
HbA1c value
Time frame: 3 months
Time in range
Time in range (glucose 70-180 mg/dl)
Time frame: 3 months
Body weight
Body weight measurement
Time frame: 3 months
Lipid profile
Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglicerides
Time frame: 3 months
Plan to share: Yes — Deidentified individual participant data and the study protocol will be made available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: after publication, till 5 yrs
Access criteria: via email:mwrobel@sum.edu.pl
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 16 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pancrelipase
Silesian Centre for Heart Diseases